Why the study?
Do direct oral anticoagulants (DOACs) prevent recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with cancer associated thrombosis (CAT)?
Do direct oral anticoagulants (DOACs) prevent recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with cancer associated thrombosis (CAT)?
In patients with cancer-associated thrombosis, DOACs are more effective than LMWHs for preventing recurrent VTE but carry a slightly higher absolute risk (2-3%) of major bleeding.
Answers are grounded in this paper and cite their sources.
Supports DOAC selection over LMWH in cancer-associated thrombosis with bleeding vigilance; confirms the efficacy-bleeding trade-off in absolute terms.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: